alexa Characterization of Antimicrobial Susceptibility Profile of Biofield Treated Multidrug-resistant <em>Klebsiella oxytoca</em> | OMICS International
ISSN: 2471-9315
Applied Microbiology: Open Access
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Characterization of Antimicrobial Susceptibility Profile of Biofield Treated Multidrug-resistant Klebsiella oxytoca

Jana S1*, Trivedi MK2, Branton A2, Trivedi D2, Nayak G2, Shettigar H2 and Gangwar M1

1Trivedi Science Research Laboratory Pvt Ltd , Hall-A, Chinar Mega Mall, Chinar Fortune City, Hoshangabad Road , Bhopal, Madhya Pradesh, India

2Trivedi Global Inc, 10624 S Eastern Avenue Suite A-969, Henderson, NV, USA

*Corresponding Author:
Jana S et al
Trivedi Science Research Laboratory Pvt Ltd
Hall-A, Chinar Mega Mall, Chinar Fortune City
Hoshangabad Rd, Bhopal, Madhya Pradesh, India
Tel: +917556660006
Email: [email protected]

Received Date: August 01, 2015 Accepted Date: October 02, 2015 Published Date: October 06, 2015

Citation: Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, Gangwar M, Jana S (2015) Characterization of Antimicrobial Susceptibility Profile of Biofield Treated Multidrug-resistant Klebsiella oxytoca. Appli Micro Open Access 1:101. doi: 10.4172/2471-9315.1000101

Copyright: © 2015 Jana S et al., This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Visit for more related articles at Applied Microbiology: Open Access

Abstract

Klebsiella are opportunistic pathogens that cause a wide spectrum of severe diseases. The aim of the present study was to investigate the impact of biofield treatment on multidrug resistant strain of K. oxytoca with respect to antibiogram pattern along with biochemical study and biotype number. Clinical lab isolate of K. oxytoca was divided into two groups i.e. control and treated. Control group remain untreated and treated group was subjected to Mr. Trivedi’s biofield. The analysis was done on day 10 after biofield treatment and compared with control group. Control and treated groups were analyzed for antimicrobial susceptibility pattern, minimum inhibitory concentration (MIC), biochemical reactions and biotype number using MicroScan Walk-Away® automated system. Experimental results showed the impact of biofield treatment on K. oxytoca and found alteration in both antimicrobial sensitivity and MIC values as compared with untreated group. Antimicrobial sensitivity of about 26.67% tested antimicrobials out of thirty was altered with respect to control. MIC results showed about 12.50% alterations in tested antimicrobials as compared to control. Biochemical study showed 24.24% alteration in tested biochemical reactions after biofield treatment. A significant change in biotype number (7713 5272) was identified after biofield treatment as compared to control (7775 4332). In treated group, a new species was identified as Kluyvera ascorbata, as compared to control, K. oxytoca. Study findings suggest that biofield treatment has a significant effect in altering the antimicrobial sensitivity, MIC values, biochemical reactions and biotype number of multidrug resistant strain of K. oxytoca. Biofield treatment could be applied to alter the antibiogram-resistogram pattern of antimicrobials.

Keywords

Klebsiella oxytoca; Multidrug resistant; Antibiogram; Biofield treatment; Biochemical reactions; Biotyping

Introduction

Klebsiella oxytoca (K. oxytoca) is a Gram-negative pathogen, cylindrical rod shaped, non-motile in nature, and belongs to Enterobacteriaceae family. Klebsiella spp . are ubiquitous in environment [1], but K. oxytoca can be cultured from intestines of healthy humans and animals, oropharynx, mucous membrane and skin. K. oxytoca initially named as Aerobacter aerogens, which was identified as Klebsiella pneumoniae , but recent report classified it as K. oxytoca, on the basis of indole-positive test and ability to grow on melezitose, not in 3-hydroxybutyrate [2]. It is considered as an opportunistic pathogen, as most of the cases K. oxytoca-infected persons remain asymptomatic. However, K. oxytoca is now recognized as important clinical pathogen in hospitalized patients causing major nosocomial infections in children and neonates [3]. It is reported in many etiological human infections such as urinary tract infection, septic arthritis, bacteremia, septicemia, cholecystitis, soft tissue infections, and most recently in colicky neonates [1,4-7]. During last few years, incidence of extended spectrum β-lactamase producing multi-drug-resistance (MDR) Klebsiella spp . had increased. Cases of MDR infections had been increased suddenly, which resulted in ineffective antimicrobials treatment. Clinicians prefer multiple combination bactericidal therapy against infection instead of single drug. Recently, an alternate approach called biofield treatment on pathogenic microorganism is reported to alter the antimicrobial susceptibility.

Biofield is a cumulative outcome of electric and magnetic field energy, exerted by the human body. However, the energy can exist in several forms such as kinetic, potential, electrical, magnetic, and nuclear. Similarly, the human nervous system consists of the energy and chemical information in the form of electrical signals. Thus, human has the ability to harness the energy from environment or universe and can transmit into any living or nonliving object(s) around the Globe. The objects always receive the energy and responding into useful way via biofield energy. Mr. Trivedi’s unique biofield treatment is also known as The Trivedi Effect®. In spite of countless study reports on biofield therapies [8,9], there are very few well controlled and peerreviewed experimental studies on pathogenic or MDR microbes. According to law of mass-energy inter-conversion [10], the conversion of mass into energy is well established, but its inversion i.e. energy into mass has not yet proved scientifically. Whenever these electrical signals fluctuate with time, the magnetic field generates as per the Ampere- Maxwell law, and cumulatively known as electromagnetic field. Mr. Trivedi’s biofield treatment is well-known to change the various physicochemical characteristics of metals and ceramics [11-14]. In addition, his unique biofield treatment has considerably altered the antimicrobials susceptibility and biochemical reactions of pathogenic microbes [15-17]. In agricultural science, biofield treatment altered the growth, characteristics and yield of important medicinal plants [18-21]. On the basis of several reports on biofield treatment, present study was designed to study the impact of biofield on MDR isolate of K. oxytoca , for its antimicrobials susceptibility pattern, minimum inhibitory concentration (MIC), along with biotyping based on variation in biochemical reactions.

Materials and Methods

Experimental design and biofield treatment

MDR clinical strain of K. oxytoca was collected from stored stock cultures of clinical sample in Microbiology Lab, Hinduja Hospital, Mumbai. MDR strain was divided in two groups i.e. control and treatment. Treatment group, in sealed pack was handed over to Mr. Trivedi for biofield treatment under laboratory conditions. Mr. Trivedi provided the treatment through his energy transmission process to the treated groups without touching the samples. The biofield treated sample was returned in the similar sealed condition for further analysis on day 10 with respect to control using the standard protocols. After biofield treatment, treated sample was analyzed for antimicrobial susceptibility, biochemical reactions and biotype number using MicroScan Walk-Away® (Dade Behring Inc., USA) and Negative Break Point Combo (NBPC 30) panel with respect to control groups. The antimicrobials and biochemicals were procured from Sigma Aldrich, MA, USA.

Evaluation of antimicrobial susceptibility assay

Antimicrobial susceptibility pattern of K. oxytoca was studied using MicroScan Walk-Away® NBPC 30 as per manufacturer's instructions. The antimicrobial susceptibility pattern (S: Susceptible, I: Intermediate, and R: Resistant) and MIC were determined by observing the lowest antimicrobial concentration showing growth inhibition [22].

Biochemical reaction study

Biochemical study of K. oxytoca was determined by MicroScan Walk-Away® system in both control and treated groups [22].

Identification by biotype number

The biotype number of K. oxytoca control and treated samples were determined by MicroScan Walk-Away® processed panel data report with the help of biochemical reactions data [22].

Results and Discussion

Antimicrobial susceptibility test

Results of antimicrobial sensitivity pattern and MIC of K. oxytoca isolate are summarized in Tables 1 and 2 respectively.

S. No. Antimicrobial Control Treated
1 Amikacin S R
2 Amoxicillin/k-clavulanate I R
3 Ampicillin/sulbactam R R
4 Ampicillin R R
5 Aztreonam EBL R
6 Cefazolin R R
7 Cefepime R R
8 Cefotaxime EBL R
9 Cefotetan S R
10 Cefoxitin R R
11 Ceftazidime EBL R
12 Ceftriaxone EBL R
13 Cefuroxime R R
14 Cephalothin R R
15 Chloramphenicol R R
16 Ciprofloxacin R R
17 ESBL-a Scrn EBL -
18 ESBL-b Scrn EBL -
19 Gatifloxacin R R
20 Gentamicin R R
21 Imipenem S S
22 Levofloxacin R R
23 Meropenem S S
24 Moxifloxacin R R
25 Piperacillin/tazobactam S I
26 Piperacillin R R
27 Tetracycline R R
28 Ticarcillin/k-clavulanate R R
29 Tobramycin R R
30 Trimethoprim/sulfamethoxazole R R

Table 1: In-vitro antimicrobial susceptibility assay of multidrug resistant Klebsiella oxytoca

S. No. Antimicrobial Control Treated
1 Amikacin ≤16 >32
2 Amoxicillin/k-clavulanate 16/8 >16/8
3 Ampicillin/sulbactam >16/8 >16/8
4 Ampicillin >16 >16
5 Aztreonam >16 >16
6 Cefazolin >16 >16
7 Cefepime >16 >16
8 Cefotaxime >32 >32
9 Cefotetan ≤16 >32
10 Cefoxitin >16 >16
11 Ceftazidime >16 >16
12 Ceftriaxone >32 >32
13 Cefuroxime >16 >16
14 Cephalothin >16 >16
15 Chloramphenicol >16 >16
16 Ciprofloxacin >2 >2
17 ESBL-a Scrn >4 >4
18 ESBL-b Scrn >1 >1
19 Gatifloxacin >4 >4
20 Gentamicin >8 >8
21 Imipenem ≤4 ≤4
22 Levofloxacin >4 >4
23 Meropenem ≤4 ≤4
24 Moxifloxacin >4 >4
25 Nitrofurantoin >64 >64
26 Norfloxacin >8 >8
27 Piperacillin/tazobactam ≤16 64
28 Piperacillin >64 >64
29 Tetracycline >8 >8
30 Ticarcillin/k-clavulanate >64 >64
31 Tobramycin >8 >8
32 Trimethoprim/sulfamethoxazole >2/38 >2/38
MIC values are presented in µg/mL; ESBL-a,bSrcn: Extended-spectrum-β-lactamase screen

Table 2: Minimum inhibitory concentration (MIC) tested antimicrobials of multidrug resistant Klebsiella oxytoca.

The biofield treatment on MDR strain of K. oxytoca showed a significant change in sensitivity pattern of different tested antimicrobials such as amikacin and cefotetan changed from sensitive (S) to resistance (R), while aztreonam, cefotaxime, ceftazidime, and ceftriaxone sensitivity were changed from suspected extendedspectrum β-lactamases to resistance. Moreover, amoxicillin/ clavulanate sensitivity changed from intermediate to resistant while piperacillin/tazobactam was changed from susceptible to intermediate as compared to control. Overall 26.67% alteration was reported out of thirty tested antimicrobials after biofield treatment. Rest of the twentytwo antimicrobials did not show any change in sensitivity after biofield treatment compared to control. MIC results showed 12.5% alteration in tested antimicrobials after biofield treatment on MDR strain of K. oxytoca . MIC value in four antimicrobials was increased out of thirtytwo tested antimicrobials. Amikacin and cefotetan showed about twofolds increase in MIC value (≤ 16 to >32 μg/mL) as compared to control. Piperacillin/tazobactam showed four folds increase in MIC value (<16 to 64 μg/mL) as compared to control. Amoxicillin/kclavulanate also showed increase MIC value with respect to control. Rest of the antimicrobials did not show any alteration in MIC values with respect to control (Table 3).

S. No. Code Biochemical Control Treated
1 ACE Acetamide - -
2 ADO Adonitol + -
3 ARA Arabinose + +
4 ARG Arginine - -
5 CET Cetrimide - +
6 CF8 Cephalothin + +
7 CIT Citrate - +
8 CL4 Colistin - -
9 ESC Esculin hydrolysis + +
10 FD64 Nitrofurantoin + +
11 GLU Glucose + +
12 H2S Hydrogen sulfide - +
13 IND Indole + +
14 INO Inositol + -
15 K4 Kanamycin + +
16 LYS Lysine + +
17 MAL Malonate + +
18 MEL Melibiose + +
19 NIT Nitrate + +
20 OF/G Oxidation-fermentation/glucose + +
21 ONPG Galactosidase + +
22 ORN Ornithine - +
23 OXI Oxidase - -
24 P4 Penicillin + +
25 RAF Raffinose + +
26 RHA Rhamnose + +
27 SOR Sorbitol + +
28 SUC Sucrose + +
29 TAR Tartrate - -
30 TDA Tryptophan deaminase - -
31 TO4 Tobramycin + +
32 URE Urea + -
33 VP Voges-Proskauer + -
 - (negative); + (positive); ONPG: Ortho-nitrophenyl-β-galactoside

Table 3: Biochemical identification of multidrug resistant Klebsiella oxytoca .

This study investigated the influence of biofield treatment on MDR strain of K. oxytoca with respect to antimicrobial sensitivity assay, and results found that biofield treatment has the potential to alter the sensitivity and MIC values of antimicrobials against biofield treated pathogen. The increased emergence of MDR strains of Klebsiella spp., in immunocompromised patients and increased infections lead to serious matter of concern worldwide. Extended spectrum β-lactamase (ESBL) producing species have still the serious problem worldwide, which may be due to continuous new drug discovery [2]. Results suggest the natural resistant pattern of MDR strain of K. oxytoca against most of the tested antimicrobials. Antimicrobial sensitivity of K. oxytoca is well supported with literature data [23]. Biofield treatment group showed significant effect on ESBL producing antimicrobials, as sensitivity after biofield treatment changed to resistant in case of aztreonam, cefotaxime, ceftazidime, and ceftriaxone. Most of the clinical strains of K. oxytoca produced chromosomal and plasmid mediated β-lactamase. Chromosomal mediated β-lactamases had the capacity to hydrolyze extended spectrum antimicrobials such as cephalosporin, and aztreonam. Mutational hyper production of β-lactamase results in a characteristic antibiogram with resistant pattern against piperacillin, cefuroxime, and aztreonam [24]. However, most of the clinical isolates of K. oxytoca have been associated with low production of β-lactamase. Biofield treatment might induce some enzymatic changes which result in significant alteration in antimicrobial sensitivity and MIC values. Resistant pattern in MDR is also associated with alteration in cell membrane, which may causes decrease uptake of antimicrobial, drug target enzyme overexpression, or alteration in drug efflux pump [25-27]. Biofield treatment in MDR K. oxytoca might alter the cell membrane permeability which results in alteration in sensitivity of tested antimicrobials.

Identification of organism by biochemical reactions

Several phenotypic identification tests are available to differentiate the Klebsiella species. Experimental identification of K. oxytoca was performed using different standard biochemical reaction analysis. Adonitol, inositol, urea, and Voges-Proskauer showed negative reaction i.e. positive to negative, while cetrimide, citrate, hydrogen sulfide, and ornithine showed positive reaction i.e. negative to positive after biofield treatment as compared to control. Rest of the biochemical reactions were not altered after biofield treatment with respect to control. Overall, biochemical reactions showed the alteration of 24.24% after biofield treatment. Experimental control biochemical reaction data of K. oxytoca are well supported with literature data [2]. Biofield treatment showed a significant alteration in positive as well as negative reactions in tested biochemical, which are the basic characteristics of K. oxytoca. The standard positive biochemical reactions of K. oxytoca were reported in case of indole, lysine decarboxylase, L-sorbose, malonate, urea and Voges-Proskauer while negative reactions in ornithine decarboxylase, gas production, and citrate.

Identification of organism by biotype number

On the basis of above biochemical changes, biotyping was performed to check the identity of microorganism after biofield treatment using an automated system. Results of biotyping found a significant changed in biotype number (7713 5272) in treated group on day 10, with respect to control (7775 4332). The organism was identified as Kluyvera ascorbata in treated group after biofield treatment as compared to control organism, K. oxytoca (Table 4). Biofield treatment on pathogenic microorganism showed significant alteration in biochemical reactions followed by altered biotype number, which are well supported with literature reports [15-17].

Feature Control Treated
Biotype 7775 4332 7713 5272
Organism Identification Klebsiellaoxytoca Kluyveraascorbata

Table 4: Effect of biofield treatment on multidrug resistant strain of Klebsiella oxytoca to its biotype number.

Biofield therapies in biomedical health care system are very popular and reported to improve human well-being with respect to several diseased conditions [28]. Increased emergence of resistant microorganisms due to widespread uses of antibiotics contributed to the spread of multidrug resistant organisms [29]. Biofield treatment is practiced by many heath care professionals as it was accepted by National Center for Complementary and Alternative Medicine (NCCAM), in complementary and alternate medicine [30]. Biofield treatment in pathogenic microorganisms had been reported to alter the antimicrobial sensitivity, phenotypic characteristics, and growth of microorganism [16,17]. It results in altered sensitivity of antimicrobials which may involve cellular changes in biofield treated K. oxytoca at molecular and/or genetic level [31]. Results showed that, biofield treatment induced changes in susceptibility pattern of antimicrobials, MIC values biochemical reactions, and biotype number of MDR strain of K. oxytoca.

Conclusion

Altogether, the biofield treatment on MDR strain of K. oxytoca showed alteration of antimicrobial sensitivity pattern, MIC, biochemical reactions followed by biotype number. Altered biochemical reactions may be responsible for changed biotype number, and a new species was identified as Kluyvera ascorbata, as compared to control. Alteration in above standard microbiological techniques after biofield treatment might involve the changes at enzymatic or genetic level of K. oxytoca, which can be further studied at molecular level with respect to altered antimicrobial sensitivity and biotype number. Based on the study outcomes, biofield treatment could be applied to alter the sensitivity pattern of antimicrobials, against multidrug resistance strain of K. oxytoca.

Acknowledgements

The authors would like to acknowledge the whole team of PD Hinduja National Hospital and MRC, Mumbai, Microbiology Lab for their support. We are very grateful for the support of Trivedi Science™, Trivedi Master Wellness™ and Trivedi Testimonials in this research work.

Conflict of interest

The authors declare that they have no competing interest.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12921
  • [From(publication date):
    December-2015 - Apr 21, 2018]
  • Breakdown by view type
  • HTML page views : 9096
  • PDF downloads : 3825
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version